A First For England's NICE - Interim Review Of Spinraza Access Agreement Gets Under Way

Review Will Determine Whether Access To Biogen's SMA Treatment Will Be Expanded

NICE will review new data in deciding whether to OK the use of Spinraza in non-ambulant SMA type III patients.

Early morning sky background, sunlight through white clouds and free birds flying away
Interim review could expand access to Spinraza

NICE, the health technology assessment (HTA) body for England and Wales, has started to review data that was collected through a managed access agreement for Biogen’s Spinraza (nusinersen) for treating the rare genetic disorder of spinal muscular atrophy. The review could see the patient population eligible to receive the drug expanded to include SMA type III patients who cannot walk.

The review is restricted to SMA type III patients who are unable to walk; this group of patients was excluded from the NICE guidance on the use under the National Health Service of Spinraza that was published in May 2019. Also see "UK Rare Disease Drug Review Reform Urged As Spinraza Finally Gets NICE OK" - Pink Sheet, 16 May, 2019

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

International Group Aims To Shape The Inevitable Future Of AI In Pharmacovigilance

 

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.

EU Wants Industry To Define ‘Trade Secrets’ Under Health Data Sharing Regulation

 

The European Health Data Space Regulation is deliberately “vague” when it comes to defining trade secrets because the EU wants the pharma industry to make recommendations on safeguarding intellectual property, a policy officer for the European Commission says.

More from Geography

Pink Sheet Podcast: A New Director For US FDA’s Biologics Center, Guidance Production Slowdowns

 

Pink Sheet editors discuss the appointment of Vinay Prasad as the new director of the Center for Biologics Evaluation and Research and revelations that FDA layoffs now are hindering development of guidance documents.

US FDA Restoring Some Library Resources

 

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals, and laid off librarians have not been reinstated.

Recent and Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.